New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Research output: Patent

Standard

New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. / Kjaer, Andreas (Inventor); Persson, Morten (Inventor); Ploug, Michael (Inventor).

IPC No.: C07K 16/ 30 A I. Patent No.: CN104768573.

Research output: Patent

Harvard

Kjaer, A, Persson, M & Ploug, M 2015, New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors, Patent No. CN104768573, IPC No. C07K 16/ 30 A I.

APA

Kjaer, A., Persson, M., & Ploug, M. (2015). IPC No. C07K 16/ 30 A I. New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. (Patent No. CN104768573).

Vancouver

Kjaer A, Persson M, Ploug M, inventors. New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. C07K 16/ 30 A I. 2015 Jul 8.

Author

Kjaer, Andreas (Inventor) ; Persson, Morten (Inventor) ; Ploug, Michael (Inventor). / New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. IPC No.: C07K 16/ 30 A I. Patent No.: CN104768573.

Bibtex

@misc{8f7e108f24f948819f2b98736f69b76d,
title = "New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors",
abstract = "There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.",
author = "Andreas Kjaer and Morten Persson and Michael Ploug",
year = "2015",
month = "7",
day = "8",
language = "English",
type = "Patent",
note = "CN104768573; C07K 16/ 30 A I",

}

RIS

TY - PAT

T1 - New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

AU - Kjaer, Andreas

AU - Persson, Morten

AU - Ploug, Michael

PY - 2015/7/8

Y1 - 2015/7/8

N2 - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

AB - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

M3 - Patent

M1 - CN104768573

ER -

ID: 178221226